The Zepbound shot is a once-weekly subcutaneous injection of tirzepatide, FDA approved in November 2023 for chronic weight management. Made by Eli Lilly, it activates two gut-hormone receptors — GIP and GLP-1 — to reduce appetite, slow digestion, and improve insulin signaling. In clinical trials, it produced average body-weight reductions of 15–21% over 72 weeks when paired with diet and activity. This is informational only: dosing and eligibility decisions belong with a licensed clinician.
What Zepbound Is Approved For
Per the FDA, Zepbound is approved for chronic weight management in adults with:
- Obesity (BMI of 30 or higher), or
- Overweight (BMI of 27 or higher) plus at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.
In December 2024 the FDA also approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
Zepbound vs. Mounjaro
Both contain tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management. The active ingredient and dosing schedule are identical. Insurance coverage often differs between the two indications.
How the Shot Works
Tirzepatide is the first dual-agonist medication in its class. It binds and activates both:
- GIP receptors (glucose-dependent insulinotropic polypeptide): enhance insulin secretion and support lipid metabolism.
- GLP-1 receptors (glucagon-like peptide-1): stimulate insulin release, suppress glucagon, slow gastric emptying, and reduce appetite centrally.
The dual action appears to produce larger weight-loss effects than single-agonist GLP-1 drugs like semaglutide (Wegovy).
Dose Schedule Overview
Zepbound is titrated slowly to minimize GI side effects. Pens come in six strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg.
| Phase | Typical Approach |
|---|---|
| Weeks 1–4 | Starting dose for tolerance, not weight loss |
| Weeks 5–8 | First maintenance step |
| Ongoing | Increase every 4+ weeks as tolerated, per clinician |
| Max | Highest approved dose if needed and tolerated |
Dose escalation decisions belong with your prescribing clinician. They depend on tolerance, response, and any interacting conditions or medications.
How to Inject
Zepbound comes in a single-dose auto-injector pen:
- Let the pen sit at room temperature for 30 minutes (optional, reduces discomfort).
- Choose a site — abdomen (2+ inches from navel), front of thigh, or back of upper arm.
- Clean the skin with an alcohol swab.
- Remove the pen cap. Press the pen against your skin at 90 degrees.
- Unlock and press the button. Hold until clicking stops (about 10 seconds).
- Dispose of the pen in a sharps container.
Rotate sites weekly. Do not reuse pens. Store unopened pens refrigerated.
Expected Results
The SURMOUNT-1 trial (NEJM 2022) tested tirzepatide in 2,539 adults with obesity over 72 weeks:
| Dose | Average Weight Loss |
|---|---|
| Placebo | 3.1% |
| Low dose | 15.0% |
| Mid dose | 19.5% |
| High dose | 20.9% |
Most weight loss happened in the first 40–60 weeks and stabilized with continued use. Stopping the medication typically leads to partial regain — Zepbound is a chronic therapy, not a short course.
Side Effects
Per the NIH MedlinePlus:
Common (more than 5% of users)
- Nausea (roughly 25–30%)
- Diarrhea
- Constipation
- Vomiting
- Decreased appetite
- Abdominal pain, indigestion
- Fatigue, especially during dose increases
- Injection-site reactions
Less Common but Serious
- Pancreatitis (severe, persistent abdominal pain — stop and seek care)
- Gallbladder disease
- Severe hypoglycemia if combined with insulin or sulfonylureas
- Kidney injury (often from dehydration due to vomiting/diarrhea)
- Allergic reactions
- Vision changes in patients with diabetic retinopathy
Boxed Warning
Tirzepatide caused thyroid C-cell tumors in rodent studies. Human risk is unknown. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Who Should Not Use Zepbound
- Personal or family history of medullary thyroid carcinoma or MEN 2
- Prior severe allergic reaction to tirzepatide
- Pregnancy or actively trying to conceive
- History of pancreatitis (use with caution)
- Severe gastroparesis
Zepbound for Prediabetes?
Zepbound is not currently FDA-approved specifically for prediabetes. However, the SURMOUNT-1 trial found tirzepatide reduced progression to type 2 diabetes by over 90% in participants with prediabetes over 3 years (SURMOUNT-1 extension). First-line treatment for prediabetes remains lifestyle change — 5–7% weight loss and 150+ minutes of weekly activity — per the ADA. Medications are typically reserved for higher-risk patients.
Cost and Access
Without insurance, list price runs roughly $1,000–$1,400 per month. Lilly offers savings programs, including a direct-to-consumer vial option at reduced cost. Insurance coverage varies widely; many plans require prior authorization and proof of BMI criteria.
Pairing Zepbound With Lifestyle
Medication is most effective alongside dietary and activity changes. Work with your clinician and ideally a registered dietitian on:
- Protein-forward meals to preserve muscle during weight loss
- Strength training 2–3 times weekly
- Adequate hydration (reduces GI side effects)
- Sleep and stress management
Our treatment hub covers the broader medication landscape, and our prediabetes 101 hub covers staging and diagnosis.
The Bottom Line
The Zepbound shot is a once-weekly tirzepatide injection FDA approved for chronic weight management. Clinical trials show substantial weight loss and improvements in related cardiometabolic markers. It has a real side-effect profile, a boxed warning, and a meaningful cost, so decisions about starting, dosing, and stopping belong with a licensed clinician — not a self-prescribed plan.
This article is educational and not a substitute for personalized medical advice. Always consult your healthcare provider about symptoms, testing, and treatment.
